Lausanne, Switzerland, July 10th , 2013 – Sensimed AG announced today the finalization of its Series C financing round for a total of CHF 25 million. An initial closing of CHF 17M of this round led by current investors Wellington Partners, Agate Medical Investments and Vinci Capital/Renaissance PME was done last October, and the remaining CHF 8M has been subscribed by Vertex Venture Management, a top tier investor based in Singapore.
FROM DEVICE TO KNOWLEDGE — Sensimed AG, a Swiss company, has developed a non-invasive soft contact lens-based solution, the SENSIMED Triggerfish® that revolutionizes glaucoma management by providing continuous 24-hour intraocular pressure-related profiles as well as modeling and analysis of patterns. The 24-hour profiles, centralized on a registry together with patient and treatment information, are processed by powerful modeling and learning algorithms identifying pathological patterns that can be used to differentiate indication, to personalize treatment, and to predict risk of progression or of conversion to glaucoma in at risk populations. Sensimed is directly positioned at the convergence between devices, treatment and information. The company believes that this global knowledge-building approach will enable ophthalmologists to better improve early diagnosis and management of patients with potentially progressive glaucomatous disease. “We’re happy to support Sensimed in bringing to market a technology that will shift the paradigm in glaucoma disease management. Our firm’s focus has been to invest in and build global leaders in specific sectors. We see Sensimed as being one of them.” Chua Kee Lock, Group CEO, Vertex Venture. Says Dr Lincoln Chee, Vertex Ventures HC Venture Partner: “We are excited to be involved with Sensimed’s technology and device that will contribute significantly to better understanding and management of glaucoma. The SENSIMED Triggerfish® is the only device that can monitor continuous pressure-related intraocular profiles and we look forward to bringing this to clinical practice.” “Sensimed is proud to have completed this round with such a strong partner.” says Sensimed CEO JeanMarc Wismer. “Besides being a strong shareholder, Vertex will also significantly contribute to the development of our activities in Asia, a region with the fastest growing incidence of glaucoma”. Further information about Sensimed AG is available on www.sensimed.ch
About Vertex Venture Holdings
Vertex Venture Holdings Ltd is a wholly-owned subsidiary of Temasek Holdings, investing in emerging companies globally. Since inception in 1988, Vertex has invested in more than 350 start-up companies, achieving substantial returns for investors, while helping over 150 portfolio companies realise their intrinsic value, through listings on capital markets in the US, Europe, Singapore, Hong Kong and Taiwan, and acquisitions by industry leaders. Headquartered in Singapore, with regional offices in Beijing, Shanghai (China), Taipei (Taiwan), Bangalore (India) and the Silicon Valley (USA), Vertex leverages the far-reaching network presence and combined experience to create value for both investors and portfolio companies. For more details on Vertex Venture please visit www.vertexventureshc.com
About Wellington Partners
Wellington Partners is among the most successful pan-European Venture Capital firms. With more than € 800 million under management and offices in Munich, London and Zurich, Wellington Partners invests in start-up companies throughout Europe that have the potential to become global leaders in the areas of digital media, resource efficiency and life sciences. Since 1998, Wellington Partners has invested in more than 100 companies, including publicly listed firms like Actelion, Evolva, Wavelight (acquired by Alcon) and Xing as well as privately held companies like AyoxxA, Grandis (acquired by Novartis), immatics, implanet, invendo medical, mtm laboratories (acquired by Roche), Oxagen, Oxford Immunotec, Quanta, Sapiens, Sensimed, Supersonic Imagine, Symetis and Spotify. For further information, please visit www.wellingtonpartners.com.
About Agate Medical Investments
Agate Medical investments LP is a group of funds, specialized in providing growth capital to mature Medtech companies. Agate, as one of Israel’s leading healthcare investors, has established a leading position in the healthcare VC industry, resulting in quality deal-flow and investor partnerships. Since its formation in September 2007, Agate has invested in 9 promising companies 8 of them are medical devices companies and one a healthcare services company. The fund is led by prominent and highly-experienced individuals with extensive medical investments knowledge and healthcare industry track record. The fund was founded by Dani Naveh, formerly Israel’s Minister of Health and Cabinet Secretary and managed by Michel Habib, formerly Israel’s Economic Consul in Boston and head of investment banking Israel for ING Bank. For more details on Agate please visit www.agate-invest.com.
About Vinci Capital/Renaissance PME
Vinci Capital is an independent Swiss private-equity firm whose mission is the financing and development of Swiss-based technology companies. Vinci Capital has an exclusive mandate to manage the funds of Renaissance PME and Mona Lisa AG. Renaissance PME is a foundation dedicated to Swiss pension funds to provide them with a fiscally optimized and regulated vehicle for direct private-equity investments. Mona Lisa AG is an investment fund by Swisscom dedicated to financing innovative Swiss SMEs with high growth potential. For further information please visit www.renaissance-pme.ch and www.vincicapital.ch.
Contact details : Sensimed AG Jean-Marc Wismer, CEO email@example.com Tel: +41 21 621 9191